ChemoCentryx, Inc.
CCXI · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $12 | $5 | $3 | $18 |
| % Growth | 115.5% | 109.1% | -85.2% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | $11 | $5 | $2 | $18 |
| % Margin | 93.2% | 96.2% | 88.4% | 100% |
| R&D Expenses | $14 | $17 | $19 | $20 |
| G&A Expenses | $0 | $26 | $56 | $20 |
| SG&A Expenses | $28 | $26 | $23 | $20 |
| Sales & Mktg Exp. | $0 | $0 | -$32 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $43 | $43 | $43 | $39 |
| Operating Income | -$31 | -$38 | -$45 | -$22 |
| % Margin | -264.1% | -696.3% | -1,734% | -123.2% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$1 |
| Pre-Tax Income | -$32 | -$39 | -$41 | -$22 |
| Tax Expense | $1 | $1 | -$5 | $0 |
| Net Income | -$32 | -$39 | -$36 | -$22 |
| % Margin | -274.1% | -718.2% | -1,370.4% | -126.1% |
| EPS | -0.45 | -0.55 | -0.51 | -0.32 |
| % Growth | 18.2% | -7.8% | -59.4% | – |
| EPS Diluted | -0.45 | -0.55 | -0.51 | -0.32 |
| Weighted Avg Shares Out | 71 | 71 | 70 | 70 |
| Weighted Avg Shares Out Dil | 71 | 71 | 70 | 70 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | -$5 | $1 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$30 | -$37 | -$44 | -$21 |
| % Margin | -255.4% | -677.7% | -1,695.1% | -116.6% |